The panel details the clinical and economic burden when patients switch between agents in plaque psoriasis.
Bhavesh Shah, PharmD
Advertisement
Articles by Bhavesh Shah, PharmD
Bhavesh Shah, PharmD, and Robert Groves, MD, discuss the priorities payers should be taking into account when managing psoriasis treatment.
Advertisement
Latest Updated Articles
Impact of Switching Agents in Plaque PsoriasisDecember 1st 2021
Utilization Management in PsoriasisDecember 1st 2021
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps
5